NorthWest Biotherapeutics Inc (NWBO)

[Smokey21]

I have tried to manage Asian workforces in a prior life. It is cheaper in direct costs, but it is a logistical nightmare to manage; especially in something as sensitive as living cell therapies. Also, I would not trust our IP anywhere in Asia at this stage.

EDEN is the way to go. Linda took the long-term view and I think it’s worth waiting for. Unlike some here, when Linda talks about franchising, I do believe that includes EDEN. We could very well distribute and control EDENs at Point-of-treatment or at other BP facilities to take control of MFG for specific indications/combinations. Most have some level of cryo storage they could take advantage of. All under the DCVax process patents and Flaskworks patents to prevent IP theft and ensure the proper royalties are collected.